CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging
China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that...
Company
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields
Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China,...
Jiangsu Hengrui’s ANGPTL3 Inhibitor SHR-1918 Earns Breakthrough Designation for HoFH Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...
Amoy Diagnostics’ AiHuiJie Lung Cancer Companion Diagnostic Receives NMPA Approval
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a biopharmaceutical company based in China, has announced...
AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup
AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the...
Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development
Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....
Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...
Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...
Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern
The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...
China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...